Explore › Finding
Finding improvement
Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4% in the sacral neuromodulation group had complete resolution of urgency incontinence (treatment difference, -16%; 95% CI, -26% to -5%; P < .001), and 46% vs 26% had at least 75% reduction (treatment difference, -20%; 95% CI, -30% to -9%; P < .001).
Effect size20% vs 4% complete resolution; 46% vs 26% >=75% reduction
CIcomplete resolution: 95% CI for difference, -26% to -5%; >=75% reduction: 95% CI for difference, -30% to -9%
Follow-up6 months
ComparatorSacral neuromodulation (InterStim)
Effect summaryimprovement; 20% vs 4% complete resolution; 46% vs 26% >=75% reduction; CI: complete resolution: 95% CI for difference, -26% to -5%; >=75% reduction: 95% CI for difference, -30% to -9%

Connected entities

Interventions
OnabotulinumtoxinA 200 unit powder for solution for injection vial
Conditions
urgency urinary incontinence
Outcomes
Complete resolution and reduction in urgency incontinence episodes

Source

PMC5399419
OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women A Randomized Clinical Trial
Read on PMC → · View in graph →